Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Variants & evidence
70 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALDH1A2 Overexpression2 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1114IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or AL… (full text at CIViC) PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1116ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 non–HPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protei… (full text at CIViC) PMID 23635773 · Kostareli et al., 2013 · Open in CIViC | civic |
| ALDH1A2 Underexpression1 | ||||||||
| Tretinoin | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1115FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrea… (full text at CIViC) PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC | civic |
| AREG Expression2 | ||||||||
| Unspecified therapy | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 3 | rejected | EID84747 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | accepted | EID84647 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| AURKB Overexpression1 | ||||||||
| Alisertib + Barasertib + CopanlisibCombination | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10836Concurrent inhibition of both AURKB (and AURKA) and PI3K is synergistic in NOTCH1-wild type and NOTCH-1 mutant head and neck squamous cell carcinoma (HNSCC) cell lines. In NOTCH1-wt cell lines, the co… (full text at CIViC) PMID 36169922 · Shah et al., 2022 · Open in CIViC | civic |
| BRAF V600E1 | ||||||||
| Vemurafenib | Laryngeal Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5962The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC | civic |
| CCND1 Overexpression1 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID357Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma. PMID 16309541 · Thomas et al., 2005 · Open in CIViC | civic |
| CD274 Expression1 | ||||||||
| Radiation Therapy | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 4 | accepted | EID3000Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC) PMID 28476872 · Skinner et al., 2017 · Open in CIViC | civic |
| CD44 CD44v91 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID9396In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC) PMID 25751671 · Aso et al., 2015 · Open in CIViC | civic |
| CDKN1B EXPRESSION1 | ||||||||
| Cisplatin + FluorouracilCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID88941 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response … (full text at CIViC) PMID 24239278 · Moreno-Galindo et al., 2014 · Open in CIViC | civic |
| CDKN2A p16 Expression7 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Better Outcome | 4 | accepted | EID695p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma. PMID 24799460 · Argiris et al., 2014 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID804Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expre… (full text at CIViC) PMID 25267748 · Chung et al., 2014 · Open in CIViC | civic |
| Afatinib | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | accepted | ||
| AFF2 Fusion1 | ||||||||
| Pembrolizumab | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID7304The primary tumor of A patient with head and neck squamous cell carcinoma with lung metastasis was not surgically resectable. Initial treatments led to stable disease and progression after 1 year. The… (full text at CIViC) PMID 31011208 · Yang et al., 2019 · Open in CIViC | civic |
| DPYD EXON 11-19 DELETION1 | ||||||||
| Fluorouracil + LeucovorinCombination | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID7787A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome ana… (full text at CIViC) PMID 31871216 · Majounie et al., 2020 · Open in CIViC | civic |
| EGF EXPRESSION1 | ||||||||
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID8263 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC) PMID 25677871 · Ansell et al., 2016 · Open in CIViC | civic |
| EGFR Amplification3 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID473The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC) PMID 16943533 · Chung et al., 2006 · Open in CIViC | civic |
| Afatinib + Cetuximab + ErlotinibSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9674This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| Cetuximab + Fluorouracil + Platinum Compound | ||||||||
| EGFR Copy Number Variation1 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID472In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and dis… (full text at CIViC) PMID 17538160 · Temam et al., 2007 · Open in CIViC | civic |
| EGFR Overexpression3 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID782Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC) PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC | civic |
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID692EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC) PMID 23265711 · Licitra et al., 2013 · Open in CIViC | civic |
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | ||||||
| EGFR P546S1 | ||||||||
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | — | submitted | EID4672bp] In an in vitro study, a NIH3T3 cell line expressing EGFR P546S mutation demonstrated increased sensitivity to cetuximab treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity w… (full text at CIViC) PMID 23578570 · Bahassi et al., 2013 · Open in CIViC | civic |
| EGFR VIII1 | ||||||||
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | accepted | EID84847 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| ERBB2 Overexpression1 | ||||||||
| Lapatinib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1992Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and … (full text at CIViC) PMID 28061634 · Seim et al., 2017 · Open in CIViC | civic |
| ERBB2 S1050L1 | ||||||||
| Afatinib + Cetuximab + ErlotinibSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9680In an in vitro study, a head and neck squamous cell carcinoma cell line OSC-19 expressing ERBB2 (HER2) S1050L mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib treatment… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| ERBB3 R1202W1 | ||||||||
| Cetuximab + ErlotinibSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9681In an in vitro study, an head and neck squamous cell carcinoma (HNSCC) cell line KYSE270 expressing ERBB3 (HER3) R1202W mutation was associated with insensitivity to cetuximab and erlotinib treatments… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| ERBB4 G1109C2 | ||||||||
| Afatinib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9676This retrospective preclinical study assessed the efficacy of afatinib towards head-and-neck squamous cell carcinoma (HNSCC) human cell lines expressing ERBB4 (HER4) G1109C mutation. According to the … (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| Erlotinib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | — | submitted | EID4809In an in vitro study, a head and neck squamous cell carcinoma cell line SAS expressing ERBB4 (HER4) G1109C was associated with insensitivity to erlotinib treatment (IC50=1.47uM). Resistance was determ… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| FGFR1 Expression3 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID970Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF an… (full text at CIViC) PMID 16454808 · Hase et al., 2006 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 1 | accepted | EID798This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. The authors conclude that evidence was found for prognostic value of FGFR1 expression in cancer-associated fibro… (full text at CIViC) PMID 26115874 · Ipenburg et al., 2016 · Open in CIViC | civic |
| Infigratinib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports | ||||
| FGFR2 P253R1 | ||||||||
| Pazopanib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7833FGFR2 p.P253R mutation detected in patient with head and neck SCC. Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing. Patient is 52 y/o male with initial diagnosis of SCC of … (full text at CIViC) PMID 23786770 · Liao et al., 2013 · Open in CIViC | civic |
| GAS6 EXPRESSION1 | ||||||||
| (prognostic) | Oral Cavity Squamous Cell CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1657128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC) PMID 26207647 · Jiang et al., 2015 · Open in CIViC | civic |
| HRAS G12V1 | ||||||||
| Alpelisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 1 | submitted | EID9087In this preclinical study, cell lines with constitutively-active G12V mutant found that forced overexpression of HRAS G12V caused a reduced susceptibility to PI3K inhibitor BYL719 in comparison to wil… (full text at CIViC) PMID 30115483 · Ruicci et al., 2018 · Open in CIViC | civic |
| HRAS Mutation1 | ||||||||
| Tipifarnib | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID9633In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of… (full text at CIViC) PMID 33750196 · Ho et al., 2021 · Open in CIViC | civic |
| KRAS RS617643701 | ||||||||
| Cisplatin | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 3 | accepted | EID872In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC) PMID 25081901 · Chung et al., 2014 · Open in CIViC | civic |
| LGR5 delta51 | ||||||||
| (prognostic) | Oral Cavity Squamous Cell CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID9621In a clinical trial including 78 patients, expression of delta5 is significantly associated with decreased OS (p = 0.02) and DFS (p = 0.01) by multivariate analysis. PMID 30770730 · Rot et al., 2019 · Open in CIViC | civic |
| MAPK1 E278E1 | ||||||||
| Erlotinib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4607A stage IVA head and neck squamous cell carcinoma patient with MAPK1 E322K mutation was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy daily for 13… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC | civic |
| MAPK1 E322K2 | ||||||||
| Erlotinib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID791Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mu… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | — | submitted | EID4797In an in vitro study, a HSC-6 cell line expressing MAPK1 E322K mutation was associated with sensitivity to erlotinib treatment, compared to Cal33 cells expressing wild-type MAPK1. Sensitivity was dete… (full text at CIViC) PMID 27004400 · Wen et al., 2016 · Open in CIViC | civic |
| NOTCH1 Loss-of-function2 | ||||||||
| Bimiralisib | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13292In a phase II, nonrandomized, single-arm trial (NCT03740100), 8 patients with recurrent/metastatic HNSCC harboring NOTCH1 mutations predicted to cause loss of function received bimiralisib after prior… (full text at CIViC) PMID 36124629 · Johnson et al., 2022 · Open in CIViC | civic |
| Porcupine Inhibitor WNT974 | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1525In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome seq… (full text at CIViC) PMID 24277854 · Liu et al., 2013 · Open in CIViC | civic |
| NRAS G13V1 | ||||||||
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | submitted | EID3035From 31 patients with advanced cutaneous squamous cell carcinomas evaluated for mutations in RAS, BRAF, and EGFR genes, only 2 RAS mutated samples (6.5%) were identified. Patients with NRAS p.G12D (c.… (full text at CIViC) PMID 28259104 · Picard et al., 2017 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
EID1155Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 2… (full text at CIViC) PMID 25892145 · Machiels et al., 2015 · Open in CIViC |
| civic |
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Does Not Support Resistance | 4 | accepted | EID697In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assaye… (full text at CIViC) PMID 24577089 · Pogorzelski et al., 2014 · Open in CIViC | civic |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Head and Neck Squamous Cell Carcinoma | Predictive | B | Does Not Support Resistance | 3 | accepted | EID694In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 pati… (full text at CIViC) PMID 24577117 · Vermorken et al., 2014 · Open in CIViC | civic |
| Panitumumab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 3 | accepted | EID696In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab)… (full text at CIViC) PMID 23746666 · Vermorken et al., 2013 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID753p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone. PMID 23746666 · Vermorken et al., 2013 · Open in CIViC | civic |
| Head and Neck Squamous Cell Carcinoma |
| Predictive |
| B |
| Does Not Support Sensitivity Response |
| 4 |
| accepted |
EID691EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study. PMID 21048039 · Licitra et al., 2011 · Open in CIViC |
| civic |
| B |
| Does Not Support Sensitivity Response |
| 3 |
| accepted |
EID84947 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC |
| civic |
| 3 |
| accepted |
EID799FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts. PMID 26015511 · Göke et al., 2015 · Open in CIViC |
| civic |